valine has been researched along with Cardiovascular Stroke in 155 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (1.29) | 18.7374 |
| 1990's | 7 (4.52) | 18.2507 |
| 2000's | 111 (71.61) | 29.6817 |
| 2010's | 35 (22.58) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fang, S; He, H; Hua, Y; Huang, Y; Li, R; Liang, S; Liu, P; Tian, Y; Xu, F; Yang, X; Yuan, Y; Zhang, Z | 1 |
| Kondo, T; Maeda, K; Matsushita, K; Muramatsu, T; Murohara, T; Nagahiro, T; Shintani, S; Yamashita, K | 1 |
| Cai, Y; He, L; He, X; He, Y; Luo, J; Wu, X; Zhang, G; Zhang, Z | 1 |
| Chen, H; Hu, X; Jiang, Z; Li, J; Liu, X; Steinhoff, G; Wang, L; Xu, Y; Yu, H; Zhang, Z | 1 |
| Campbell, DJ; Koid, SS; Ziogas, J | 1 |
| Califf, RM; Kober, L; Lewis, EF; Li, Y; Pfeffer, MA; Reed, SD; Rouleau, JL; Schulman, KA; Solomon, SD; Velazquez, EJ; Weinfurt, KP; White, HD | 1 |
| Chou, YM; Ghasemi, O; Iyer, RP; Jin, YF; Levin, DB; Lindsey, ML; Lopez, EF; Ramirez, TA; Zamilpa, R; Zhang, J | 1 |
| Bathgate-Siryk, A; Dabul, S; Garcia, D; Koch, WJ; Lymperopoulos, A; McDonald, P; Rengo, G; Sturchler, E; Walklett, K | 1 |
| Güleç, S | 1 |
| Cheng, WP; Lo, HM; Shyu, KG; Wang, BW | 1 |
| Akasaka, T; Goto, M; Ikejima, H; Imanishi, T; Kobayashi, K; Kuroi, A; Mochizuki, S; Muragaki, Y; Shiomi, M; Tsujioka, A; Tsujioka, H; Yoshida, K | 1 |
| Bethel, MA; Califf, RM; Haffner, SM; Holman, R; Hua, TA; Huntsman-Labed, A; McMurray, J | 1 |
| Fu, L; Gao, Y; Han, Y; Li, Y; Ma, D; Shen, J; Wang, F; Wang, Y; Xie, R; Zhou, P | 1 |
| Bader, M; Carretero, OA; Rhaleb, NE; Shesely, EG; Xu, J; Yang, JJ; Yang, XP | 1 |
| Hawkins, NM; Huang, Z; Kober, L; Maggioni, AP; McMurray, JJ; Pfeffer, MA; Pieper, KS; Solomon, SD; Swedberg, K; Velazquez, EJ | 1 |
| Chaplin, S; Papo, NL; Scuffham, PA; Taylor, M | 1 |
| Bayir, Y; Halici, Z; Keles, MS; Suleyman, H | 1 |
| Huang, CX; Jiang, H; Li, GS; Okello, E; Tang, YH; Wang, X; Zhao, QY | 1 |
| Geshi, E; Katagiri, T; Mochizuki, S; Nakano, H; Nanjyo, S; Sato, N; Shibata, T; Suzuki, H; Takano, T; Tanaka, K; Yagi, H; Yamazaki, J | 1 |
| Arnold, JM; Bourgoun, M; Califf, RM; Ghali, JK; Kober, L; McMurray, JJ; Meris, A; Pfeffer, MA; Skali, H; Solomon, SD; Velazquez, EJ; Verma, A | 1 |
| Miura, T; Yuda, S | 1 |
| Califf, RM; Maggioni, AP; McMurray, JJ; Moukarbel, GV; Pfeffer, MA; Scheiman, JM; Signorovitch, JE; Solomon, SD; Velazquez, EJ; White, HD | 1 |
| Califf, RM; Diaz, R; Leimberger, JD; Lewis, EF; Lokhnygina, Y; McMurray, JJ; Murin, J; Pfeffer, MA; Velazquez, EJ | 1 |
| Li, D; Ma, S; Tang, B; Yang, D; Yang, Y | 1 |
| Huang, YL; Li, JJ; Qu, XF; Shen, JX; Wang, GZ; Xi, Y; Xiu, CH; Yue, L | 1 |
| Al-Khatib, SM; Califf, RM; McMurray, JJ; Pfeffer, MA; Piccini, JP; Pieper, K; Solomon, SD; Van de Werf, F; Velazquez, EJ; Zhang, M | 1 |
| Bourgoun, M; Califf, RM; Ghali, JK; Hassanein, AH; Hung, CL; Køber, L; Pfeffer, MA; Shin, SH; Solomon, SD; Uno, H; Velazquez, EJ; Verma, A | 1 |
| Aihara, K; Akimoto, Y; Daida, H; Kasai, T; Kawamura, M; Kojima, S; Miyauchi, K; Miyazaki, S; Miyazaki, T; Sumiyoshi, M; Suwa, S; Takagi, A | 1 |
| Finckenberg, P; Kaheinen, P; Levijoki, J; Louhelainen, M; Merasto, S; Mervaala, E; Vahtola, E | 1 |
| Bode, C; Braunwald, E; Cannon, CP; Lopez-Sendon, J; Lukashevich, V; Maboudian, M; McCabe, CH; Morrow, DA; Ogorek, M; Oude Ophuis, AJ; Rifai, N; Ruda, M; Ruzyllo, W; Scirica, BM; Swedberg, K | 1 |
| Belenkov, Y; Califf, RM; Finn, PV; Kenchaiah, S; Kober, L; Maggioni, AP; McMurray, JJ; Pfeffer, MA; Shamshad, F; Soler-Soler, J; Solomon, SD; Swedberg, K; Varshavsky, S; Velazquez, EJ | 1 |
| Califf, R; Kober, L; Maggioni, A; McMurray, JJ; Pfeffer, MA; Rouleau, J; Signorovitch, JE; Solomon, SD; Swedberg, K; Thune, JJ; Velazquez, E | 1 |
| Campo, G; Cangiano, E; Carrà, G; Ceconi, C; Ferrari, R; Fortini, C; Francolini, G; Marchesini, J; Miccoli, M; Tavazzi, L | 1 |
| Akhter, N; Alom, MM; Bhuiyan, NI; Rozario, RJ | 1 |
| Higashikuni, Y; Hirata, Y; Iwata, H; Nagai, R; Sata, M; Takaoka, M; Tanaka, K | 1 |
| Birnbaum, Y; Castillo, AC; Perez-Polo, JR; Qian, J; Ye, Y | 1 |
| Hasegawa, H; Kobayashi, Y; Komuro, I; Kuwabara, Y; Mizuma, H; Narumi, H; Shindo, S; Takano, H | 1 |
| Kimura, S; Matsubara, H; Sawada, T; Shiraishi, J; Yamada, H | 1 |
| Baek, H; Cho, YR; Choi, SY; Hong, TJ; Hur, SH; Hwang, JY; Kim, KS; Kim, YD; Lee, SG; Park, JS; Park, K; Park, TH; Yang, TH | 1 |
| Chen, RH; Jiao, KL; Li, YG; Yu, Y; Zhang, PP | 1 |
| Amigoni, M; Califf, R; Køber, L; Levine, RA; McMurray, JJ; Meris, A; Pfeffer, MA; Solomon, SD; Thune, JJ; Velazquez, E; Verma, A | 1 |
| Albayrak, A; Bayir, Y; Ferah, I; Halici, Z; Kabalar, E; Karakus, E; Keles, MS; Keles, O; Unal, B | 1 |
| Ebina, T; Hibi, K; Kimura, K; Kosuge, M; Kusama, I; Morita, S; Nozawa, N; Okuda, J; Ozaki, H; Tsukahara, K; Umemura, S; Yano, H | 1 |
| Burchill, LJ; Burrell, LM; Dean, RG; Griggs, K; Patel, SK; Velkoska, E | 1 |
| Kariž, S; Nikolajević Starčević, J; Petrovič, D | 1 |
| Benge, CD; Muldowney, JA | 1 |
| Brunner, HR; Hua, TA; Jia, Y; Julius, S; Kjeldsen, SE; Mancia, G; McInnes, GT; Schork, A; Weber, MA; Zanchetti, A; Zappe, DH | 1 |
| Chujo, M; Hashimoto, T; Ishigaki, M; Kohro, T; Yamazaki, T | 1 |
| Kanorskiĭ, SG; Shevelev, VI | 1 |
| Lee, TH | 1 |
| Carretero, OA; Kapke, A; Liu, YH; Shesely, EG; Xu, J; Yang, F; Yang, XP | 1 |
| Krum, H; Martin, J | 1 |
| Sato, H | 1 |
| Bedigian, MP; Falk, SA; Gengaro, PE; Gurevich, AK; Nemenoff, RA; Rizeq, M; Schrier, RW; Summer, SN; Weinberger, HD | 1 |
| Abuzeid, AM; Hawe, E; Humphries, SE; Talmud, PJ | 1 |
| Genda, S; Ichikawa, Y; Kuno, A; Matsumoto, T; Miki, T; Miura, T; Sakamoto, J; Shimamoto, K; Tanno, M | 1 |
| Califf, RM; Edwards, S; Gallo, P; Henis, M; Kober, L; Leimberger, JD; Maggioni, AP; McMurray, JV; Pfeffer, MA; Rouleau, JL; Sellers, MA; Swedberg, K; Van de Werf, F; Velazquez, EJ; White, HD | 1 |
| Jugdutt, BI; Menon, V | 3 |
| Hashimoto, R; Kawahara, S; Matsuzaki, M; Umemoto, S | 1 |
| Pegoraro, RJ; Ranjith, N; Rom, L | 1 |
| Deswal, A; Mann, DL | 1 |
| Califf, RM; Edwards, S; Henis, M; Køber, L; Leimberger, JD; Maggioni, AP; McMurray, JJ; Pfeffer, MA; Rouleau, JL; Sellers, MA; Solomon, SD; Swedberg, K; Van de Werf, F; Velazquez, EJ; White, H; Zelenkofske, S | 1 |
| Pfeffer, M | 1 |
| McAnulty, JH | 1 |
| Kupfer, Y; Moshenyat, R; Tessler, S | 1 |
| Jorde, UP | 1 |
| Lai, KN; Lam, KY; Leung, JC; Li, PS; Wing-Hon Lai, K; Yu, CM | 1 |
| Liebson, PR | 1 |
| McMurray, JJ; Swedberg, K | 1 |
| Piña, IL | 1 |
| Hasenfuss, G | 1 |
| Williams, B | 1 |
| Solignac, M | 1 |
| Aguilar, D; Belenkov, YN; Califf, RM; Diaz, R; Francis, GS; Henis, M; Køber, L; Leimberger, JD; McMurray, JJ; O'Connor, CM; Pfeffer, MA; Rouleau, JL; Skali, H; Solomon, SD; Varshavsky, S; Velazquez, EJ | 1 |
| Anavekar, NS; Califf, RM; Dickstein, K; Kober, L; Leimberger, JD; Maggioni, A; McMurray, JJ; Nordlander, R; Pfeffer, MA; Rouleau, JL; Solomon, SD; Velazquez, EJ; White, HD; Zelenkofske, S | 1 |
| Nguyen, A; Sharma, S | 1 |
| Jugdutt, BI; Menon, V; Sawicki, G | 1 |
| Jugdutt, BI; Sawicki, G | 2 |
| Zidek, W | 1 |
| Croom, KF; Keating, GM | 1 |
| Strauss, M; Verma, S | 1 |
| Caturla, J; Corral, J; González-Conejero, R; Lee, KW; Lip, GY; López, F; Marín, F; Roldán, V; Sogorb, F; Vicente, V | 1 |
| Fabbri, G; Maggioni, AP | 1 |
| Aliavi, BA; Grachev, AV; Iakubov, MM; Kremkova, MM; Masri, MA | 1 |
| Anavekar, NS; Arnold, JM; Barvik, S; Bourgoun, M; Califf, RM; Ghali, JK; Khrakovskaya, M; McMurray, JV; Pfeffer, MA; Schwartz, Y; Skali, H; Solomon, SD; Velazquez, EJ; Warnica, JW | 1 |
| Bönner, G; Heintz, D; Kandra, A; Khder, Y; Malacco, E; Ruilope, LM | 1 |
| Allsbrook, JS; Califf, RM; Masselink, LE; McMurray, JJ; Pfeffer, MA; Radeva, JI; Reed, SD; Schulman, KA; Sellers, MA; Velazquez, EJ; Weinfurt, KP | 1 |
| Califf, RM; Diaz, R; Ertl, G; Hernandez, AF; Kilaru, R; Maggioni, AP; O'Connor, CM; Pfeffer, MA; Rouleau, JL; Solomon, SD; van Gilst, W; Velazquez, EJ | 1 |
| Aylward, PE; Barvik, S; Califf, RM; Dalby, AJ; Huang, Z; Marin-Neto, JA; McMurray, JJ; Murin, J; Nordlander, RO; Pfeffer, MA; van Gilst, WH; Weaver, WD; White, HD; Zannad, F | 1 |
| Califf, R; Howlett, J; Køber, L; Maggioni, A; McMurray, J; Pfeffer, M; Pieper, K; Reed, S; Rouleau, J; Solomon, S; Swedberg, K; Van de Werf, F; Velazquez, E; White, H | 1 |
| Anavekar, N; McMurray, J; Pfeffer, M; Skali, H; Solomon, SD; Velazquez, E; Yerra, L; Zelenkofske, S | 1 |
| Bilge, AK; Diz-Kucukkaya, R; Ergen, G; Hancer, VS; Nalcaci, M; Oncul, A; Ozben, B | 1 |
| Califf, RM; Diaz, R; Ertl, G; Køber, L; Leimberger, JD; Maggioni, AP; Mareev, V; McMurray, JJ; Opolski, G; Pfeffer, MA; Rouleau, JL; Solomon, SD; Swedberg, K; Van de Werf, F; Velazquez, EJ; Zannad, F; Zelenkofske, S | 1 |
| Kjeldsen, SE; Mistry, NB; Westheim, AS | 1 |
| Aldeghi, A; Calcagnino, M; Emanuele, E; Falcone, C; Geroldi, D; Minoretti, P; Mori, F; Olivieri, V | 1 |
| Cheung, BM | 1 |
| Burghină, D; Cozma, D; Dan, R; Drăgulescu, SI; Petrescu, L; Riviş, AI; Suşan, M; Suşan, RM | 1 |
| Cheng, JL; Gao, RL; Jing, ZC; Wu, YJ; Yang, YJ; You, SJ; Zhao, JL | 1 |
| Dessì-Fulgheri, P; Sarzani, R | 1 |
| Califf, RM; Diaz, R; Kober, L; Maggioni, AP; Mareev, V; McMurray, JJ; Murin, J; Reed, SD; Schulman, KA; Van de Werf, F; Velazquez, EJ; White, HD | 1 |
| Higaki, J; Okura, T | 1 |
| Liu, PP; Maggioni, A; Velazquez, EJ | 1 |
| Akishita, M; Horiuchi, M; Oishi, Y; Oshima, T; Ozono, R; Yoshizumi, M | 1 |
| Anavekar, NS; Arnold, JM; Bourgoun, M; Ghali, JK; Køber, L; Pfeffer, MA; Skali, H; Solomon, SD; Thune, JJ; Velazquez, EJ | 1 |
| Imaizumi, S; Iwata, A; Kiya, Y; Kumagai, K; Matsuo, K; Miura, S; Nishikawa, H; Saku, K; Shimomura, H; Shirai, K; Zhang, B | 1 |
| Pfeffer, MA | 2 |
| Jugdutt, BI | 1 |
| Aylward, PG; Califf, RM; Kober, L; McMurray, JJ; Pfeffer, MA; Pieper, KS; Skali, H; Solomon, SD; Stephenson, K; Van de Werf, F; Velazquez, EJ; White, HD | 1 |
| Ott, P | 1 |
| Anderson, JL; Doucette, SP; Gagnon, F; Scarvelis, D; Shafey, M; Wells, PS | 1 |
| Cui, RZ; Liu, GQ; Mao, YM; Sun, GY; Sun, J; Zhang, SS; Zhao, HM | 1 |
| Azuma, J; Dosaka, N; Iekushi, K; Katsuragi, N; Koibuchi, N; Morishita, R; Nagao, K; Ogihara, T; Sanada, F; Taniyama, Y | 1 |
| Bose, AK; Carr, RD; Mocanu, MM; Yellon, DM | 1 |
| Akazawa, H; Komuro, I; Kudo, Y | 1 |
| Ahmed, A; Husain, A; Perry, GJ | 1 |
| Aksnes, TA; Hua, TA; Julius, S; Kjeldsen, SE; Omvik, P; Rostrup, M | 1 |
| Bissessor, N; White, H | 1 |
| Victor, RG | 1 |
| Califf, RM; Howlett, J; Kober, L; Maggioni, AP; McMurray, JJ; Pfeffer, MA; Rouleau, JL; Signorovitch, J; Solomon, SD; Thune, JJ; Velazquez, EJ; Zelenkofske, S | 1 |
| Al-Khatib, SM; Califf, RM; Kober, L; Lokhnygina, Y; McMurray, JJ; Solomon, SD; Thomas, KL; Velazquez, EJ | 1 |
| Gaballa, MA; Goldman, S; Guarraia, D; Johnson, N; Thai, H | 1 |
| Anavekar, NS; Califf, R; Kober, L; Maggioni, A; McMurray, JJ; Pfeffer, MA; Rouleau, JL; Solomon, SD; Velazquez, E; White, H | 1 |
| Anderson, RE; Califf, RM; Maggioni, A; McMurray, JJ; Pfeffer, MA; Rouleau, JL; Skali, H; Solomon, SD; Thune, JJ; Velazquez, E; White, HD | 1 |
| Liu, ZY; Sun, GY; Zhang, SS | 1 |
| Havranek, EP | 1 |
| Califf, RM; Francis, GS; Huang, Z; Lewis, EF; McMurray, JJ; Pfeffer, MA; Prisant, LM; Thomas, KL; Velazquez, EJ; Weaver, WD | 1 |
| Holm, J; Norlund, L; Ohlin, AK; Zöller, B | 1 |
| Fujimura, Y; Hayashi, N; Kometani, M; Nakao, K; Yamamoto, S | 1 |
| Carter, A; Grant, PJ; Kohler, HP; Mikkola, H; Ossei-Gerning, N; Stickland, MH | 1 |
| Bowron, A; Gudnason, V; Humphries, S; Nicaud, V; Scott, J; Stansbie, D | 1 |
| Arveiler, D; Aumont, MC; de Prost, D; Desprez, S; Dhermy, D; Evans, A; Fumeron, F; Galand, C; Garbarz, M; Hakim, J; Luc, G; Moatti, D; Ollivier, V; Poirier, O; Ruidavets, JB; Seknadji, P | 1 |
| De Gasparo, M; Fornes, P; Gervais, M; Giudicelli, JF; Richer, C | 1 |
| Carey, RM; Siragy, HM | 1 |
| Califf, R; Edwards, S; Gallo, P; Henis, M; Leizorovicz, A; Maggioni, AP; McMurray, J; Neuhart, E; Pfeffer, MA; Rouleau, JL; Sellers, MA; Van De Werf, F; Velazquez, E | 1 |
| Sandmann, S; Unger, T; Yu, M | 1 |
| Fukuma, T; Hasegawa, T; Miki, T; Miura, T; Nakano, A; Shimamoto, K; Tsuchida, A | 1 |
| Hannan, RD; Krum, H; Lim, S; See, F; Tzanidis, A; Ugoni, AM | 1 |
| Lau, CP; Tipoe, GL; Wing-Hon Lai, K; Yu, CM | 1 |
| Hasegawa, T; Kuno, A; Miki, T; Miura, T; Nishino, Y; Shimamoto, K; Tsuchida, A | 1 |
| Kirby, DA; Lown, B; Maher, TJ; Pinto, JM | 1 |
| Aburaya, T; Ichihara, A; Shirai, A; Takemoto, T | 1 |
| Samofalova, MS | 1 |
20 review(s) available for valine and Cardiovascular Stroke
| Article | Year |
|---|---|
Valsartan after myocardial infarction.
Topics: Angiotensin II Type 1 Receptor Blockers; Humans; Myocardial Infarction; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2014 |
Determining the most appropriate components for a composite clinical trial outcome.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Diseases; Clinical Trials as Topic; Data Collection; Endpoint Determination; Humans; Myocardial Infarction; Odds Ratio; Outcome Assessment, Health Care; Research Design; Stroke; Tetrazoles; Valine; Valsartan | 2008 |
The pharmacokinetics and pharmacodynamics of valsartan in the post-myocardial infarction population.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Dose-Response Relationship, Drug; Drug Evaluation; Humans; Hypertension; Myocardial Infarction; Randomized Controlled Trials as Topic; Risk Factors; Tetrazoles; Valine; Valsartan | 2012 |
Role of valsartan and other angiotensin receptor blocking agents in the management of cardiovascular disease.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Cardiac Output, Low; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus; Humans; Hypertension; Hypertrophy, Left Ventricular; Kidney Failure, Chronic; Myocardial Infarction; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2002 |
[Acute myocardial infarction].
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Captopril; Clinical Trials as Topic; Coronary Restenosis; Female; Humans; Losartan; Male; Middle Aged; Myocardial Infarction; Tetrazoles; Valine; Valsartan | 2002 |
[Angiotensin receptor blockers in chronic heart failure].
Topics: Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Double-Blind Method; Heart Failure; Humans; Hypertension; Japan; Losartan; Myocardial Infarction; Neurotransmitter Agents; Randomized Controlled Trials as Topic; Risk Factors; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left; Ventricular Remodeling | 2003 |
VALUE and supremacy of blood pressure control for cardiovascular protection.
Topics: Antihypertensive Agents; Humans; Hypertension; Myocardial Infarction; Stroke; Tetrazoles; Valine; Valsartan | 2004 |
Valsartan: a review of its use in patients with heart failure and/or left ventricular systolic dysfunction after myocardial infarction.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Clinical Trials as Topic; Heart Failure; Humans; Myocardial Infarction; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2004 |
[Use of the antihypertensive agent Diovan after acute myocardial infarction].
Topics: Antihypertensive Agents; Clinical Trials as Topic; Humans; Myocardial Infarction; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2005 |
The angiotensin receptor antagonist valsartan: a review of the literature with a focus on clinical trials.
Topics: Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Diabetes Mellitus; Drug Administration Schedule; Heart Failure; Humans; Hypertension; Myocardial Infarction; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan | 2006 |
Therapeutic potential of angiotensin receptor blockers in hypertension.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Coronary Disease; Female; Humans; Hypertension; Losartan; Male; Meta-Analysis as Topic; Myocardial Infarction; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Survival Analysis; Tetrazoles; Valine; Valsartan | 2006 |
[VALUE].
Topics: Aged; Aged, 80 and over; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Calcium Channel Blockers; Double-Blind Method; Endpoint Determination; Humans; Hypertension; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Randomized Controlled Trials as Topic; Risk; Tetrazoles; Valine; Valsartan | 2006 |
Will more complete inhibition of the RAAS with angiotensin receptor blockade improve survival following myocardial infarction?
Topics: Angiotensin II Type 1 Receptor Blockers; Humans; Myocardial Infarction; Renin-Angiotensin System; Survival; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2000 |
Valsartan in the treatment of heart attack survivors.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiac Output, Low; Humans; Myocardial Infarction; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Research Design; Secondary Prevention; Tetrazoles; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction, Left; Ventricular Remodeling | 2006 |
Factor XIII Val34Leu variant and the risk of myocardial infarction: a meta-analysis.
Topics: Adult; Factor XIII; Female; Gene Frequency; Genetic Predisposition to Disease; Genotype; Humans; Leucine; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Risk Assessment; Risk Factors; Valine | 2007 |
[Pharmocological therapeutics for chronic heart failure--how to use ARB (angiotensin receptor blocker].
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl Compounds; Chronic Disease; Clinical Trials as Topic; Drug Therapy, Combination; Heart Failure; Humans; Losartan; Myocardial Infarction; Severity of Illness Index; Survival Rate; Tetrazoles; Valine; Valsartan | 2007 |
Valsartan in the treatment of heart failure or left ventricular dysfunction after myocardial infarction.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Drug Therapy, Combination; Heart Failure; Humans; Myocardial Infarction; Renin-Angiotensin System; Tetrazoles; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction, Left | 2007 |
Pathophysiology of target-organ disease: does angiotensin II remain the key?
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Calcium Channel Blockers; Cardiovascular Diseases; Disease Progression; Humans; Hypertension; Losartan; Myocardial Infarction; Renin; Renin-Angiotensin System; Stroke; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2007 |
Enhancing cardiac protection after myocardial infarction: rationale for newer clinical trials of angiotensin receptor blockers.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Clinical Trials as Topic; Heart Failure; Humans; Myocardial Infarction; Prognosis; Receptors, Angiotensin; Renin-Angiotensin System; Risk Factors; Tetrazoles; Valine; Valsartan; Ventricular Function, Left | 2000 |
Prospective trials of angiotensin receptor blockers: beyond blood pressure control.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Humans; Hypertension; Losartan; Myocardial Infarction; Tetrazoles; Valine; Valsartan | 2000 |
39 trial(s) available for valine and Cardiovascular Stroke
| Article | Year |
|---|---|
Effects of valsartan versus amlodipine in diabetic hypertensive patients with or without previous cardiovascular disease.
Topics: Aged; Amlodipine; Antihypertensive Agents; Cardiovascular Diseases; Case-Control Studies; Death, Sudden, Cardiac; Diabetes Mellitus, Type 2; Female; Heart Failure; Hospitalization; Humans; Hypertension; Male; Middle Aged; Myocardial Infarction; Myocardial Reperfusion; Proportional Hazards Models; Stroke; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2013 |
Impact of cardiovascular events on change in quality of life and utilities in patients after myocardial infarction: a VALIANT study (valsartan in acute myocardial infarction).
Topics: Acute Disease; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Bundle-Branch Block; Captopril; Death, Sudden, Cardiac; Drug Therapy, Combination; Female; Health Status; Heart Failure; Hospitalization; Humans; Male; Myocardial Infarction; Quality of Life; Recurrence; Stroke; Survivors; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2014 |
Determining the most appropriate components for a composite clinical trial outcome.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Diseases; Clinical Trials as Topic; Data Collection; Endpoint Determination; Humans; Myocardial Infarction; Odds Ratio; Outcome Assessment, Health Care; Research Design; Stroke; Tetrazoles; Valine; Valsartan | 2008 |
Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atherosclerosis; Cause of Death; Confidence Intervals; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Prognosis; Proportional Hazards Models; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Survival Rate; Tetrazoles; Time Factors; Valine; Valsartan | 2009 |
Inhibitory effect of valsartan against progression of left ventricular dysfunction after myocardial infarction: T-VENTURE study.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Asian People; Disease Progression; Female; Humans; Japan; Male; Middle Aged; Myocardial Infarction; Stroke Volume; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction, Left; Ventricular Remodeling | 2009 |
Prognostic implications of left ventricular mass and geometry following myocardial infarction: the VALIANT (VALsartan In Acute myocardial iNfarcTion) Echocardiographic Study.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Cardiovascular Diseases; Europe; Female; Heart Ventricles; Humans; Hypertrophy, Left Ventricular; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Predictive Value of Tests; Proportional Hazards Models; Recurrence; Risk Assessment; Risk Factors; Tetrazoles; Time Factors; Treatment Outcome; Ultrasonography; United States; Valine; Valsartan; Ventricular Remodeling | 2008 |
Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT Trial.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Anticoagulants; Female; Gastrointestinal Hemorrhage; Heart Failure; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk Factors; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2009 |
Usefulness of beta blockers in high-risk patients after myocardial infarction in conjunction with captopril and/or valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] trial).
Topics: Acute Disease; Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Captopril; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Prospective Studies; Risk Assessment; Risk Factors; Survival Analysis; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2009 |
Predictors of sudden cardiac death change with time after myocardial infarction: results from the VALIANT trial.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Captopril; Death, Sudden, Cardiac; Double-Blind Method; Female; Hospitalization; Humans; Male; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Recurrence; Risk Factors; Stroke Volume; Tetrazoles; Time Factors; Valine; Valsartan; Ventricular Dysfunction, Left | 2010 |
Changes of matrix metalloproteinase-9 level is associated with left ventricular remodeling following acute myocardial infarction among patients treated with trandolapril, valsartan or both.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Drug Therapy, Combination; Female; Humans; Indoles; Male; Matrix Metalloproteinase 9; Middle Aged; Myocardial Infarction; Tetrazoles; Treatment Outcome; Valine; Valsartan; Ventricular Remodeling | 2010 |
Patients with acute coronary syndromes and elevated levels of natriuretic peptides: the results of the AVANT GARDE-TIMI 43 Trial.
Topics: Acute Coronary Syndrome; Aged; Amides; Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Female; Fumarates; Hospitalization; Humans; Male; Middle Aged; Myocardial Infarction; Natriuretic Peptide, Brain; Peptide Fragments; Renin; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2010 |
Fatal myocardial rupture after acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: the VALsartan In Acute myocardial iNfarcTion Trial (VALIANT).
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Cause of Death; Female; Follow-Up Studies; Heart Failure; Heart Rupture, Post-Infarction; Humans; Male; Middle Aged; Myocardial Infarction; Prognosis; Retrospective Studies; Tetrazoles; Time Factors; Valine; Valsartan; Ventricular Dysfunction, Left | 2010 |
Predictors and prognostic impact of recurrent myocardial infarction in patients with left ventricular dysfunction, heart failure, or both following a first myocardial infarction.
Topics: Age Factors; Aged; Captopril; Cause of Death; Confidence Intervals; Drug Therapy, Combination; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Recurrence; Risk Assessment; Severity of Illness Index; Sex Factors; Survival Analysis; Tetrazoles; Time Factors; Valine; Valsartan; Ventricular Dysfunction, Left | 2011 |
ACE inhibition modulates endothelial apoptosis and renewal via endothelial progenitor cells in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antigens, CD34; Apoptosis; Bone Marrow Cells; Case-Control Studies; Cells, Cultured; Endothelial Cells; Female; Humans; Male; Middle Aged; Myocardial Infarction; Perindopril; Single-Blind Method; Stem Cells; Tetrazoles; Umbilical Veins; Valine; Valsartan | 2011 |
Effects of valsartan and amlodipine on home blood pressure and cardiovascular events in Japanese hypertensive patients: a subanalysis of the VART.
Topics: Aged; Albuminuria; Amlodipine; Angina Pectoris; Antihypertensive Agents; Asian People; Blood Pressure; Cardiovascular Diseases; Cause of Death; Creatinine; Death, Sudden; Female; Heart Failure; Humans; Hypertension; Hypertrophy, Left Ventricular; Kidney Failure, Chronic; Male; Middle Aged; Myocardial Infarction; Stroke; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2012 |
Combination effect of calcium channel blocker and valsartan on cardiovascular event prevention in patients with high-risk hypertension: ancillary results of the KYOTO HEART Study.
Topics: Aged; Angina Pectoris; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cardiovascular Diseases; Female; Heart Failure; Humans; Hypertension; Japan; Male; Middle Aged; Myocardial Infarction; Risk Factors; Stroke; Tetrazoles; Valine; Valsartan | 2012 |
The impact of dose of the angiotensin-receptor blocker valsartan on the post-myocardial infarction ventricular remodeling: study protocol for a randomized controlled trial.
Topics: Adult; Aged; Angiotensin II Type 2 Receptor Blockers; Clinical Protocols; Female; Humans; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Sample Size; Single-Blind Method; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left; Ventricular Remodeling | 2011 |
Mechanisms and predictors of mitral regurgitation after high-risk myocardial infarction.
Topics: Adult; Age Factors; Aged; Angiotensin-Converting Enzyme Inhibitors; Captopril; Disease Progression; Echocardiography, Doppler, Color; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Middle Aged; Mitral Valve Insufficiency; Monitoring, Physiologic; Multivariate Analysis; Myocardial Infarction; Predictive Value of Tests; Prospective Studies; Reference Values; Reproducibility of Results; Risk Assessment; ROC Curve; Severity of Illness Index; Sex Factors; Statistics, Nonparametric; Stroke Volume; Tetrazoles; Time Factors; Valine; Valsartan; Ventricular Dysfunction, Left; Ventricular Remodeling | 2012 |
Effects of valsartan, an angiotensin II receptor blocker, on coronary atherosclerosis in patients with acute myocardial infarction who receive an angiotensin-converting enzyme inhibitor.
Topics: Aged; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biomarkers; Blood Pressure; Captopril; Chi-Square Distribution; Coronary Artery Disease; Drug Therapy, Combination; Female; Humans; Hypertrophy, Left Ventricular; Japan; Logistic Models; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Odds Ratio; Predictive Value of Tests; Prospective Studies; Renin-Angiotensin System; Risk Assessment; Risk Factors; Tetrazoles; Time Factors; Treatment Outcome; Ultrasonography, Interventional; Valine; Valsartan | 2012 |
Cardiovascular outcomes in hypertensive patients: comparing single-agent therapy with combination therapy.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Prognosis; Retrospective Studies; Stroke; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2012 |
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Captopril; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combination; Female; Heart Failure; Humans; Male; Middle Aged; Myocardial Infarction; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2003 |
[AT(1) blocker for post-infarct therapy. VALIANT Study].
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Captopril; Cause of Death; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Survival Analysis; Syndrome; Tetrazoles; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction, Left | 2004 |
[Results of the VALIANT trial in post-myocardial infarction].
Topics: Adult; Aftercare; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Body Mass Index; Captopril; Cause of Death; Coronary Angiography; Double-Blind Method; Echocardiography; Female; Hospitalization; Humans; Male; Myocardial Infarction; Patient Selection; Proportional Hazards Models; Risk Factors; Stroke Volume; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2004 |
Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Captopril; Cardiovascular Diseases; Chronic Disease; Creatinine; Double-Blind Method; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Humans; Kidney Diseases; Male; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Risk Factors; Survival Rate; Tetrazoles; Valine; Valsartan | 2004 |
Heart attack patients with complications. Treat with valsartan, captopril, or both?
Topics: Aged; Antihypertensive Agents; Captopril; Double-Blind Method; Drug Therapy, Combination; Female; Heart Failure; Humans; Male; Middle Aged; Myocardial Infarction; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2004 |
VALIANT (VALsartan In Acute myocardial iNfarcTion) trial.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Captopril; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Myocardial Infarction; Tetrazoles; Valine; Valsartan | 2005 |
[A comparative assessment of valsartan and lisinopril effects on systolic and diastolic function of the left ventricular in patients with acute Q-infarction].
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Diastole; Electrocardiography; Female; Follow-Up Studies; Humans; Lisinopril; Male; Middle Aged; Myocardial Contraction; Myocardial Infarction; Systole; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2005 |
Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Captopril; Drug Therapy, Combination; Electrocardiography; Female; Heart Ventricles; Hospitalization; Humans; Hypertrophy, Left Ventricular; Male; Middle Aged; Myocardial Infarction; Prognosis; Stroke Volume; Tetrazoles; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction, Left | 2005 |
Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
Topics: Age Factors; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Cerebrovascular Disorders; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypercholesterolemia; Hypertension; Male; Middle Aged; Myocardial Infarction; Obesity; Risk Factors; Tetrazoles; Valine; Valsartan | 2005 |
Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT).
Topics: Ambulatory Care; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Captopril; Drug Costs; Global Health; Health Care Costs; Health Resources; Heart Failure; Hospital Costs; Hospitalization; Humans; Myocardial Infarction; Prospective Studies; Quality of Life; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2005 |
Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarct
Topics: Age Factors; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Captopril; Cardiovascular Diseases; Cause of Death; Heart Failure; Humans; Middle Aged; Morbidity; Mortality; Myocardial Infarction; Systole; Tetrazoles; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction, Left | 2005 |
Previously known and newly diagnosed atrial fibrillation: a major risk indicator after a myocardial infarction complicated by heart failure or left ventricular dysfunction.
Topics: Acute Disease; Aged; Angiotensin II Type 1 Receptor Blockers; Atrial Fibrillation; Captopril; Cardiac Output, Low; Female; Humans; Male; Middle Aged; Myocardial Infarction; Outcome Assessment, Health Care; Prognosis; Proportional Hazards Models; Risk Assessment; Risk Factors; Survival Analysis; Tetrazoles; Time Factors; Valine; Valsartan; Ventricular Dysfunction, Left | 2006 |
Dual renin angiotensin system blockade in patients with acute myocardial infarction and preserved left ventricular systolic function.
Topics: Acute Disease; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Drug Therapy, Combination; Female; Humans; Male; Myocardial Infarction; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left; Ventricular Function, Left | 2005 |
Do valsartan and losartan have the same effects in the treatment of coronary artery disease?
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Case-Control Studies; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; Coronary Stenosis; Dose-Response Relationship, Drug; Female; Humans; Intercellular Adhesion Molecule-1; L-Selectin; Losartan; Male; Middle Aged; Myocardial Infarction; Tetrazoles; Valine; Valsartan | 2007 |
Long-term outcomes of left bundle branch block in high-risk survivors of acute myocardial infarction: the VALIANT experience.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Bundle-Branch Block; Captopril; Electrocardiography; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Predictive Value of Tests; Proportional Hazards Models; Research Design; Risk Factors; Stroke Volume; Survival Analysis; Survivors; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction, Left | 2007 |
Impact of new-onset diabetes mellitus on cardiac outcomes in the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial population.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Diabetes Complications; Diabetic Angiopathies; Double-Blind Method; Drug Administration Schedule; Female; Heart Failure; Heart Rate; Humans; Hypertension; Incidence; Male; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Tetrazoles; Valine; Valsartan | 2007 |
Amiodarone use after acute myocardial infarction complicated by heart failure and/or left ventricular dysfunction may be associated with excess mortality.
Topics: Aged; Amiodarone; Captopril; Cause of Death; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Heart Failure; Humans; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Probability; Proportional Hazards Models; Reference Values; Risk Assessment; Severity of Illness Index; Survival Analysis; Tetrazoles; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction | 2008 |
Comparison of renal function and cardiovascular risk following acute myocardial infarction in patients with and without diabetes mellitus.
Topics: Aged; Antihypertensive Agents; Captopril; Cardiovascular Diseases; Creatinine; Diabetes Complications; Double-Blind Method; Female; Glomerular Filtration Rate; Humans; Kidney; Kidney Diseases; Male; Middle Aged; Myocardial Infarction; Risk Factors; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2008 |
High-risk myocardial infarction in the young: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial.
Topics: Adult; Age Factors; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Diseases; Diabetes Complications; Female; Humans; Hypertension; Kaplan-Meier Estimate; Male; Middle Aged; Mortality; Multivariate Analysis; Myocardial Infarction; Proportional Hazards Models; Risk Factors; Sex Factors; Smoking; Survivors; Tetrazoles; Valine; Valsartan | 2008 |
97 other study(ies) available for valine and Cardiovascular Stroke
| Article | Year |
|---|---|
Time Series Characteristics of Serum Branched-Chain Amino Acids for Early Diagnosis of Chronic Heart Failure.
Topics: Animals; Area Under Curve; Biomarkers; Disease Models, Animal; Disease Progression; Early Diagnosis; Heart Failure; Leucine; Machine Learning; Male; Metabolome; Metabolomics; Myocardial Infarction; Rats; Rats, Sprague-Dawley; ROC Curve; Valine | 2019 |
Induction of autophagy contributes to the myocardial protection of valsartan against ischemia‑reperfusion injury.
Topics: Adenine; Animals; Autophagy; Cardiotonic Agents; Hemodynamics; Ischemic Preconditioning; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Proto-Oncogene Proteins c-akt; Rats; Rats, Sprague-Dawley; Ribosomal Protein S6 Kinases; Signal Transduction; Tetrazoles; TOR Serine-Threonine Kinases; Valine; Valsartan | 2013 |
Preconditioning via angiotensin type 2 receptor activation improves therapeutic efficacy of bone marrow mononuclear cells for cardiac repair.
Topics: Angiotensin II; Animals; Apoptosis; Bone Marrow Cells; Cell Transplantation; Coculture Techniques; Echocardiography; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Inflammation; Leukocytes, Mononuclear; Male; Myocardial Infarction; Myocytes, Cardiac; Neovascularization, Physiologic; Nitric Oxide; Nitric Oxide Synthase Type III; Oligopeptides; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Stem Cell Transplantation; Tetrazoles; Valine; Valsartan; Vascular Endothelial Growth Factor A | 2013 |
Aliskiren reduces myocardial ischemia-reperfusion injury by a bradykinin B2 receptor- and angiotensin AT2 receptor-mediated mechanism.
Topics: Amides; Angiotensin II Type 2 Receptor Blockers; Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Bradykinin; Bradykinin B2 Receptor Antagonists; Cardiotonic Agents; Drug Therapy, Combination; Female; Fumarates; Imidazoles; Models, Animal; Myocardial Infarction; Myocardial Reperfusion Injury; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 2; Receptor, Bradykinin B2; Tetrazoles; Valine; Valsartan | 2014 |
Aliskiren and valsartan mediate left ventricular remodeling post-myocardial infarction in mice through MMP-9 effects.
Topics: Amides; Animals; Antihypertensive Agents; Drug Therapy, Combination; Extracellular Matrix; Female; Fumarates; Gene Expression; Male; Matrix Metalloproteinase 9; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardial Infarction; Myocardium; Stroke Volume; Survival Analysis; Systole; Tetrazoles; Valine; Valsartan; Ventricular Function, Left; Ventricular Remodeling | 2014 |
Different potencies of angiotensin receptor blockers at suppressing adrenal β-Arrestin1-dependent post-myocardial infarction hyperaldosteronism.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Hyperaldosteronism; Myocardial Infarction; Rats; Tetrazoles; Valine; Valsartan | 2014 |
MicroRNA-208a Increases Myocardial Endoglin Expression and Myocardial Fibrosis in Acute Myocardial Infarction.
Topics: Animals; Atorvastatin; Blotting, Western; Cells, Cultured; Disease Models, Animal; Endoglin; Fibrosis; Gene Expression Regulation; Hemodynamics; Heptanoic Acids; Immunohistochemistry; Intracellular Signaling Peptides and Proteins; Male; MicroRNAs; Muscle Cells; Myocardial Infarction; Polymerase Chain Reaction; Pyrroles; Random Allocation; Rats; Rats, Sprague-Dawley; Sensitivity and Specificity; Tetrazoles; Valine; Valsartan; Ventricular Remodeling | 2015 |
Combined effects of an 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor and angiotensin II receptor antagonist on nitric oxide bioavailability and atherosclerotic change in myocardial infarction-prone Watanabe heritable hyperlipidemic rabbits.
Topics: Acetylcholine; Angiotensin II Type 1 Receptor Blockers; Animals; Atherosclerosis; Biological Availability; Drug Therapy, Combination; Echocardiography; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Myocardial Infarction; Nitric Oxide; Quinolines; Rabbits; Reactive Oxygen Species; Tetrazoles; Tyrosine; Valine; Valsartan | 2008 |
Interventional effect of valsartan on expression of inducible cAMP early repressor and phosphodiesterase 3A in rats after myocardial infarction.
Topics: Angiotensin Receptor Antagonists; Animals; Apoptosis; Cardiomegaly; Cyclic AMP Response Element Modulator; Cyclic AMP Response Element-Binding Protein; Cyclic Nucleotide Phosphodiesterases, Type 3; Gene Expression Regulation; Heart; Heart Failure; Myocardial Infarction; Myocardium; Rats; Tetrazoles; Valine; Valsartan; Ventricular Remodeling | 2009 |
The kinin B1 receptor contributes to the cardioprotective effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Collagen; Disease Models, Animal; Female; Heart Rate; Hypertrophy, Left Ventricular; Ligation; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardial Infarction; Myocytes, Cardiac; Ramipril; Receptor, Bradykinin B1; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2009 |
An economic evaluation of valsartan for post-MI patients in the UK who are not suitable for treatment with ACE inhibitors.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cost-Benefit Analysis; Data Collection; Decision Making; Humans; Kaplan-Meier Estimate; Marketing; Markov Chains; Models, Economic; Models, Statistical; Myocardial Infarction; Psychometrics; Quality-Adjusted Life Years; Tetrazoles; Time Factors; United Kingdom; Valine; Valsartan | 2009 |
Investigation of effects of Lacidipine, Ramipril and Valsartan on DNA damage and oxidative stress occurred in acute and chronic periods following isoproterenol-induced myocardial infarct in rats.
Topics: Animals; Antihypertensive Agents; Biomarkers; Dihydropyridines; DNA Damage; Guanine; Isoproterenol; Myocardial Infarction; Nitric Oxide; Oxidative Stress; Ramipril; Rats; Tetrazoles; Valine; Valsartan | 2009 |
Acetylcholine-regulated K+ current remodelling in the atrium after myocardial infarction and valsartan administration.
Topics: Acetylcholine; Angiotensin II Type 1 Receptor Blockers; Animals; Atrial Appendage; Atrial Fibrillation; Heart Atria; Myocardial Infarction; Patch-Clamp Techniques; Potassium Channels; Rabbits; Tetrazoles; Valine; Valsartan | 2009 |
Are treatment effects of ACEI and ARB in post-MI patients homogeneous?
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Asian People; Disease Progression; Humans; Myocardial Infarction; Stroke Volume; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction, Left; Ventricular Remodeling | 2009 |
Angiotensin II receptor blockade improves matrix metalloproteinases/tissue inhibitor of matrix metalloproteinase-1 balance and restores fibronectin expression in rat infarcted myocardium.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Fibronectins; Imidazoles; Male; Matrix Metalloproteinases; Myocardial Infarction; Pyridines; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Tetrazoles; Tissue Inhibitor of Metalloproteinase-1; Valine; Valsartan | 2009 |
[On angiotensin II receptor distribution after myocardial infarction in dogs].
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Dogs; Female; Male; Myocardial Infarction; Myocardium; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; RNA, Messenger; Tetrazoles; Valine; Valsartan | 2009 |
Mechanical dyssynchrony after myocardial infarction in patients with left ventricular dysfunction, heart failure, or both.
Topics: Aged; Analog-Digital Conversion; Angiotensin II Type 1 Receptor Blockers; Death; Disease Progression; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Motion; Myocardial Contraction; Myocardial Infarction; Prognosis; Proportional Hazards Models; Stress, Mechanical; Tetrazoles; Ultrasonography; Valine; Valsartan; Ventricular Dysfunction, Left; Video Recording | 2010 |
Effects of the calcium sensitizer OR-1896, a metabolite of levosimendan, on post-infarct heart failure and cardiac remodelling in diabetic Goto-Kakizaki rats.
Topics: Acetamides; Animals; Biomarkers; Cardiac Volume; Cellular Senescence; Diabetes Mellitus, Type 2; Fibrosis; Heart Failure; Inflammation; Mitochondria, Heart; Myocardial Infarction; Myocytes, Cardiac; Pyridazines; Random Allocation; Rats; Tetrazoles; Time Factors; Valine; Valsartan; Vasodilator Agents; Ventricular Pressure | 2010 |
Antioxidant effect of valsartan in experimental model of myocardial infarction.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aspartate Aminotransferases; Creatine Kinase, MB Form; Epinephrine; Erythrocytes; Female; Glutathione; Male; Malondialdehyde; Models, Animal; Myocardial Infarction; Oxidative Stress; Rats; Tetrazoles; Valine; Valsartan | 2011 |
Aliskiren in combination with valsartan exerts synergistic protective effects against ventricular remodeling after myocardial infarction in mice.
Topics: Amides; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Pressure; Drug Synergism; Fumarates; Heart; Lipid Peroxidation; Male; Mice; Myocardial Infarction; Myocardium; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan; Ventricular Remodeling | 2012 |
[Antihypertensive therapy in routine practice: fixed or free combination? Fixed combination scores with better prognosis].
Topics: Amlodipine; Amlodipine, Valsartan Drug Combination; Antihypertensive Agents; Drug Combinations; Humans; Hydrochlorothiazide; Hypertension; Medication Adherence; Myocardial Infarction; Stroke; Tetrazoles; Valine | 2011 |
Aliskiren and Valsartan reduce myocardial AT1 receptor expression and limit myocardial infarct size in diabetic mice.
Topics: Administration, Oral; Amides; Angiotensin II Type 1 Receptor Blockers; Animals; Diabetes Mellitus, Experimental; Drug Therapy, Combination; Fumarates; Hemodynamics; Immunoblotting; Male; Mice; Mice, Inbred Strains; Myocardial Infarction; Myocardial Reperfusion Injury; Receptor, Angiotensin, Type 1; Renin; Tetrazoles; Valine; Valsartan | 2011 |
Effects of valsartan on ventricular arrhythmia induced by programmed electrical stimulation in rats with myocardial infarction.
Topics: Animals; Arrhythmias, Cardiac; Connexin 43; Down-Regulation; Electric Stimulation; Female; Myocardial Infarction; Rats; Real-Time Polymerase Chain Reaction; Receptor, Angiotensin, Type 1; Tetrazoles; Up-Regulation; Valine; Valsartan | 2012 |
Comparing effects of lacidipine, ramipril, and valsartan against experimentally induced myocardial infarcted rats.
Topics: Administration, Oral; Animals; Cardiotonic Agents; Dihydropyridines; Dose-Response Relationship, Drug; Isoproterenol; Male; Myocardial Infarction; Ramipril; Rats; Rats, Sprague-Dawley; Tetrazoles; Valine; Valsartan | 2012 |
Combination renin-angiotensin system blockade and angiotensin-converting enzyme 2 in experimental myocardial infarction: implications for future therapeutic directions.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inhibitors; Angiotensins; Animals; Drug Therapy, Combination; Female; Gene Expression Regulation, Enzymologic; Heart; Hemodynamics; Immunohistochemistry; Myocardial Infarction; Myocardium; Organ Size; Peptidyl-Dipeptidase A; Ramipril; Rats; Rats, Sprague-Dawley; Renin; Renin-Angiotensin System; Reverse Transcriptase Polymerase Chain Reaction; Tetrazoles; Valine; Valsartan | 2012 |
Association of manganese superoxide dismutase and glutathione S-transferases genotypes with myocardial infarction in patients with type 2 diabetes mellitus.
Topics: Alanine; Biomarkers; Blood Glucose; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Genetic Predisposition to Disease; Genotype; Glutathione S-Transferase pi; Glutathione Transferase; Humans; Lipids; Logistic Models; Male; Middle Aged; Myocardial Infarction; Oxidative Stress; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Polymorphism, Single Nucleotide; Risk Factors; Slovenia; Superoxide Dismutase; Valine; White People | 2012 |
The occurrence rate of cerebrovascular and cardiac events in patients receiving antihypertensive therapy from the post-marketing surveillance data for valsartan in Japan (J-VALID).
Topics: Aged; Angina Pectoris; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cerebral Hemorrhage; Cerebral Infarction; Cerebrovascular Disorders; Female; Health Surveys; Heart Failure; Humans; Hypertension; Incidence; Japan; Male; Middle Aged; Myocardial Infarction; Product Surveillance, Postmarketing; Prospective Studies; Registries; Retrospective Studies; Stroke; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2013 |
[Antihypertensive therapy and dynamics of vascular wall rigidity in elderly patients with non-valvular atrial fibrillation].
Topics: Aged; Ankle Brachial Index; Anticholesteremic Agents; Antihypertensive Agents; Arterial Pressure; Arteries; Atrial Fibrillation; Combined Modality Therapy; Drug Monitoring; Female; Fluorobenzenes; Humans; Hypertension; Male; Myocardial Infarction; Perindopril; Pulse Wave Analysis; Pyrimidines; Rosuvastatin Calcium; Stroke; Sulfonamides; Tetrazoles; Treatment Outcome; Ultrasonography, Doppler, Duplex; Valine; Valsartan; Vascular Resistance | 2012 |
Ask the doctor. I have had heart failure since my heart attack a year ago. My physician initially prescribed lisinopril, an angiotensin-converting enzyme (ACE) inhibitor. Unfortunately, I was one of the unlucky people who got a cough with this drug that w
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cough; Heart Failure; Humans; Lisinopril; Myocardial Infarction; Tetrazoles; Valine; Valsartan | 2002 |
Role of AT2 receptors in the cardioprotective effect of AT1 antagonists in mice.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Cardiotonic Agents; Collagen; Enalapril; Heart Rate; Hemodynamics; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardial Infarction; Myocardium; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Renin; Survival Analysis; Tetrazoles; Valine; Valsartan; Ventricular Remodeling | 2002 |
Effects of angiotensin receptor blockade on haemodynamics and gene expression after myocardial infarction.
Topics: Angiotensin Receptor Antagonists; Animals; Gene Expression Regulation; Hemodynamics; Hypertrophy, Left Ventricular; Male; Myocardial Infarction; Rats; Rats, Sprague-Dawley; Receptors, Angiotensin; Tetrazoles; Valine; Valsartan | 2002 |
Association between the Ala379Val variant of the lipoprotein associated phospholipase A2 and risk of myocardial infarction in the north and south of Europe.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Alanine; Alleles; Case-Control Studies; Europe; Gene Frequency; Genetic Predisposition to Disease; Genetic Variation; Genotype; Homozygote; Humans; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Phospholipases A; Phospholipases A2; Valine | 2003 |
Interruption of signal transduction between G protein and PKC-epsilon underlies the impaired myocardial response to ischemic preconditioning in postinfarct remodeled hearts.
Topics: Adenosine; Angiotensin II Type 1 Receptor Blockers; Animals; Cytosol; GTP-Binding Proteins; In Vitro Techniques; Ischemic Preconditioning, Myocardial; Male; Myocardial Infarction; Myocardial Reperfusion; Protein Kinase C; Protein Kinase C-epsilon; Protein Transport; Rabbits; Receptors, Purinergic P1; Signal Transduction; Tetrazoles; Valine; Valsartan; Ventricular Remodeling | 2003 |
VALsartan In Acute myocardial iNfarcTion (VALIANT) trial: baseline characteristics in context.
Topics: Aged; Angiotensin Receptor Antagonists; Captopril; Double-Blind Method; Female; Glyceraldehyde-3-Phosphate Dehydrogenases; Heart Failure; Humans; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Peptide Fragments; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2003 |
Upregulation of angiotensin II type 2 receptor and limitation of myocardial stunning by angiotensin II type 1 receptor blockers during reperfused myocardial infarction in the rat.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Animals; Biphenyl Compounds; Electrocardiography; Irbesartan; Myocardial Infarction; Myocardial Reperfusion; Myocardium; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrazoles; Up-Regulation; Valine; Valsartan; Ventricular Function, Left | 2003 |
Haemostatic gene polymorphisms in young indian asian subjects with acute myocardial infarction.
Topics: Adolescent; Adult; Alleles; Factor V; Family Health; Genotype; Hemostasis; Heterozygote; Humans; India; Middle Aged; Myocardial Infarction; Polymorphism, Genetic; Prothrombin; Risk Factors; Smoking; Thrombomodulin; Valine | 2003 |
Angiotensin-receptor blockade in acute myocardial infarction--a matter of dose.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Captopril; Drug Therapy, Combination; Heart Failure; Humans; Myocardial Infarction; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2003 |
[Value in heart failure proven again. AT II blocker soon also for post-infarct patients?].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Captopril; Clinical Trials as Topic; Drug Therapy, Combination; Heart Failure; Humans; Myocardial Infarction; Survival Rate; Tetrazoles; Valine; Valsartan | 2003 |
Valsartan an alternative to ACE inhibitor in high-risk MI.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Captopril; Humans; Myocardial Infarction; Randomized Controlled Trials as Topic; Receptors, Angiotensin; Tetrazoles; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction, Left | 2004 |
[When after myocardial infarction a pump weakness remains. ACE inhibitors and AT-1 blockers equivalent].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Captopril; Double-Blind Method; Drug Therapy, Combination; Heart Failure; Humans; Myocardial Infarction; Randomized Controlled Trials as Topic; Tetrazoles; Time Factors; Valine; Valsartan; Ventricular Dysfunction, Left | 2003 |
[New options against undertreatment].
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Captopril; Clinical Trials as Topic; Heart Failure; Hospitalization; Humans; Losartan; Myocardial Infarction; Risk Factors; Stroke Volume; Tetrazoles; Time Factors; Valine; Valsartan | 2003 |
Valsartan-induced cardioprotection involves angiotensin II type 2 receptor upregulation in dog and rat models of in vivo reperfused myocardial infarction.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Animals; Antihypertensive Agents; Blood Pressure; Disease Models, Animal; Dogs; Myocardial Infarction; Myocardial Reperfusion; Myocardium; Random Allocation; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrazoles; Treatment Outcome; Up-Regulation; Valine; Valsartan; Ventricular Function, Left | 2004 |
Valsartan, captopril, or both in myocardial infarction.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Captopril; Ethics, Clinical; Heart Failure; Humans; Myocardial Infarction; Placebos; Research Design; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2004 |
Valsartan, captopril, or both in myocardial infarction.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Captopril; Humans; Kidney Diseases; Myocardial Infarction; Tetrazoles; Valine; Valsartan | 2004 |
Valsartan, captopril, or both in myocardial infarction.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Captopril; Humans; Hypotension; Myocardial Infarction; Tetrazoles; Valine; Valsartan | 2004 |
Normalization of renal aquaporin-2 water channel expression by fosinopril, valsartan, and combination therapy in congestive heart failure: a new mechanism of action.
Topics: Administration, Oral; Animals; Antihypertensive Agents; Aquaporin 2; Aquaporins; Drug Therapy, Combination; Fosinopril; Gene Expression; Heart Failure; Kidney Cortex; Kidney Medulla; Male; Myocardial Infarction; Rats; Rats, Sprague-Dawley; Tetrazoles; Valine; Valsartan | 2004 |
VALIANT and EUROPA.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Captopril; Cardiovascular Diseases; Coronary Disease; Double-Blind Method; Heart Failure; Humans; Multicenter Studies as Topic; Myocardial Infarction; Perindopril; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2004 |
Angiotensin receptor blockers and heart failure: still CHARMing after VALIANT?
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Chronic Disease; Heart Failure; Humans; Myocardial Infarction; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan | 2004 |
Valsartan in acute myocardial infarction trial.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Captopril; Female; Heart Failure; Humans; Male; Myocardial Infarction; Tetrazoles; Valine; Ventricular Dysfunction, Left | 2004 |
AT1 receptor blockade limits myocardial injury and upregulates AT2 receptors during reperfused myocardial infarction.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Blood Pressure; Dogs; Heart Rate; Heart Ventricles; Hemodynamics; Irbesartan; Myocardial Infarction; Myocardial Reperfusion Injury; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrazoles; Time Factors; Valine; Valsartan; Ventricular Remodeling | 2004 |
Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Captopril; Cohort Studies; Comorbidity; Diabetes Complications; Diabetes Mellitus; Drug Therapy, Combination; Female; Follow-Up Studies; Heart Failure; Humans; Life Tables; Male; Medical Records; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Proportional Hazards Models; Randomized Controlled Trials as Topic; Risk; Stroke; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction, Left | 2004 |
Improved balance between TIMP-3 and MMP-9 after regional myocardial ischemia-reperfusion during AT1 receptor blockade.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Blotting, Western; Densitometry; Disease Models, Animal; Dogs; Electrocardiography; Electrophoresis, Gel, Two-Dimensional; Heart Rate; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Myocardial Infarction; Myocardial Reperfusion; Random Allocation; Tetrazoles; Tissue Inhibitor of Metalloproteinase-3; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction, Left | 2004 |
AT1 receptor blockade alters metabolic, functional and structural proteins after reperfused myocardial infarction: detection using proteomics.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; ATP Synthetase Complexes; Biphenyl Compounds; Creatine Kinase; Dogs; Hemodynamics; Irbesartan; Isocitrate Dehydrogenase; Myocardial Infarction; Myocardial Reperfusion Injury; Myosin Light Chains; Proteins; Proteomics; Receptor, Angiotensin, Type 1; Tetrazoles; Valine; Valsartan; Ventricular Function, Left | 2004 |
[Preventing end-organ damage in hypertension. What is the significance of the VALUE Study for general practice?].
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Calcium Channel Blockers; Cardiovascular Diseases; Cause of Death; Humans; Hypertension; Myocardial Infarction; Randomized Controlled Trials as Topic; Survival Rate; Tetrazoles; Valine; Valsartan | 2004 |
Angiotensin receptor blockers and myocardial infarction.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Humans; Hypertension; Myocardial Infarction; Tetrazoles; Truth Disclosure; Valine; Valsartan | 2004 |
A pharmacogenetic effect of factor XIII valine 34 leucine polymorphism on fibrinolytic therapy for acute myocardial infarction.
Topics: Aged; Factor XIII; Female; Genotype; Humans; Leucine; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Polymorphism, Genetic; Risk Factors; Thrombolytic Therapy; Valine | 2005 |
Left ventricular assessment in myocardial infarction: the VALIANT registry.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Cardiac Catheterization; Echocardiography; Female; Humans; Male; Middle Aged; Myocardial Infarction; Outcome Assessment, Health Care; Tetrazoles; Valine; Valsartan; Ventricular Function, Left | 2005 |
Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Captopril; Clinical Trials as Topic; Disease Progression; Drug Therapy, Combination; Heart Failure; Humans; Hypokalemia; Hypotension; Losartan; Meta-Analysis as Topic; Myocardial Infarction; Renal Insufficiency; Tetrazoles; Valine | 2005 |
The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
Topics: Aged; Angina Pectoris; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Atherosclerosis; Captopril; Cardiovascular Diseases; Disease-Free Survival; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Myocardial Infarction; Randomized Controlled Trials as Topic; Recurrence; Stroke; Tetrazoles; Valine; Valsartan | 2006 |
Association of QRS duration and outcomes after myocardial infarction: the VALIANT trial.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cohort Studies; Electrocardiography; Female; Follow-Up Studies; Heart Ventricles; Humans; Male; Middle Aged; Myocardial Infarction; Prognosis; Stroke Volume; Survival Rate; Tetrazoles; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction, Left | 2006 |
The association between factor XIII Val34Leu polymorphism and early myocardial infarction.
Topics: Adult; Age Factors; Alleles; Case-Control Studies; Coronary Thrombosis; DNA; Factor XIII; Female; Gene Frequency; Genetic Predisposition to Disease; Genotype; Humans; Leucine; Male; Middle Aged; Myocardial Infarction; Polymerase Chain Reaction; Polymorphism, Genetic; Regression Analysis; Valine | 2006 |
[Successful mega studies with heart patients. Valsartan possesses cardioprotective action].
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Captopril; Clinical Trials as Topic; Drug Therapy, Combination; Heart Failure; Humans; Hypertension; Long-Term Care; Myocardial Infarction; Secondary Prevention; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2006 |
A novel Val734Ile variant in the ABCC9 gene associated with myocardial infarction.
Topics: Alleles; Amino Acid Sequence; Animals; ATP-Binding Cassette Transporters; Conserved Sequence; Exons; Female; Genetic Variation; Genotype; Humans; Isoleucine; Male; Middle Aged; Molecular Sequence Data; Myocardial Infarction; Potassium Channels; Potassium Channels, Inwardly Rectifying; Receptors, Drug; Sequence Alignment; Sulfonylurea Receptors; Valine | 2006 |
[Scientific evidence--applied in routine general practice. Successful decrease in pressure and risk].
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Drug Therapy, Combination; Evidence-Based Medicine; Family Practice; Germany; Heart Failure; Humans; Hypertension; Myocardial Infarction; Product Surveillance, Postmarketing; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2006 |
Pretreatment with fosinopril or valsartan reduces myocardial no-reflow after acute myocardial infarction and reperfusion.
Topics: Acute Disease; Animals; Antihypertensive Agents; Blood Flow Velocity; Chemoprevention; Endothelium; Fosinopril; H(+)-K(+)-Exchanging ATPase; Models, Animal; Myocardial Infarction; Myocardial Reperfusion; Myocardium; Swine; Tetrazoles; Time Factors; Valine; Valsartan | 2006 |
Angiotensin receptor blockers and myocardial infarction: the importance of dosage.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Clinical Trials as Topic; Dose-Response Relationship, Drug; Humans; Hypertension; Myocardial Infarction; Research Design; Tetrazoles; Valine; Valsartan | 2006 |
Geographic variation in the treatment of acute myocardial infarction in the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial.
Topics: Aged; Captopril; Drug Therapy, Combination; Female; Humans; Internationality; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2006 |
Use of valsartan in post-myocardial infarction and heart failure patients.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Cardiac Output, Low; Humans; Myocardial Infarction; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2006 |
AT2 receptor mediates the cardioprotective effects of AT1 receptor antagonist in post-myocardial infarction remodeling.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Body Weight; Male; Mice; Mice, Knockout; Myocardial Infarction; Organ Size; Receptor, Angiotensin, Type 2; Survival Rate; Tetrazoles; Valine; Valsartan; Ventricular Function, Left; Ventricular Remodeling | 2006 |
[Dilemma of antihypertensive therapy: high blood pressure diminishes, potency sometimes, too].
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atenolol; Diuretics; Erectile Dysfunction; Humans; Hypertension; Male; Myocardial Infarction; Tetrazoles; Time Factors; Valine; Valsartan | 2006 |
Comparison of regional versus global assessment of left ventricular function in patients with left ventricular dysfunction, heart failure, or both after myocardial infarction: the valsartan in acute myocardial infarction echocardiographic study.
Topics: Aged; Antihypertensive Agents; Comorbidity; Echocardiography; Female; Heart Failure; Humans; Internationality; Male; Middle Aged; Myocardial Infarction; Prevalence; Prognosis; Reproducibility of Results; Risk Assessment; Risk Factors; Sensitivity and Specificity; Stroke Volume; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2006 |
Left bundle branch block is not good for your heart.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Bundle-Branch Block; Captopril; Heart Failure; Humans; Myocardial Infarction; Risk Factors; Stroke Volume; Tetrazoles; Time Factors; Valine; Valsartan; Ventricular Dysfunction, Left | 2007 |
[Effect of cilazapril and valsartan on the levels of cardiac interstitial water content in rats with acute myocardial infarction].
Topics: Animals; Antihypertensive Agents; Cilazapril; Disease Models, Animal; Male; Matrix Metalloproteinase 2; Myocardial Infarction; Myocardium; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; RNA, Messenger; Tetrazoles; Tissue Inhibitor of Metalloproteinase-1; Valine; Valsartan | 2007 |
Novel mechanisms of valsartan on the treatment of acute myocardial infarction through inhibition of the antiadhesion molecule periostin.
Topics: Acute Disease; Angiotensin II; Animals; Antihypertensive Agents; Cell Adhesion Molecules; Cell Communication; Cells, Cultured; Disease Models, Animal; Fibroblasts; Gene Expression Regulation; Male; Myocardial Infarction; Myocardium; Myocytes, Cardiac; Random Allocation; Rats; Rats, Inbred Lew; Rats, Wistar; Stress, Mechanical; Tetrazoles; Valine; Valsartan; Ventricular Remodeling | 2007 |
Valsartan reverses post-translational modifications of the delta-subunit of ATP synthase during in vivo canine reperfused myocardial infarction.
Topics: Amino Acids; Angiotensin II Type 2 Receptor Blockers; Animals; Apoptosis; Dogs; Mitochondrial Proton-Translocating ATPases; Myocardial Infarction; Myocardial Reperfusion Injury; Necrosis; Phosphorylation; Protein Processing, Post-Translational; Protein Subunits; Proteomics; Receptor, Angiotensin, Type 2; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2007 |
Myocardial ischaemia-reperfusion injury is attenuated by intact glucagon like peptide-1 (GLP-1) in the in vitro rat heart and may involve the p70s6K pathway.
Topics: Animals; Blotting, Western; Disease Models, Animal; Enzyme Inhibitors; Glucagon-Like Peptide 1; In Vitro Techniques; Incretins; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Phosphatidylinositol 3-Kinases; Protein Kinases; Pyrroles; Random Allocation; Rats; Rats, Sprague-Dawley; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction; Sirolimus; Time Factors; TOR Serine-Threonine Kinases; Valine | 2007 |
VALIDD should not invalidate angiotensin-receptor blockers.
Topics: Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Myocardial Infarction; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2007 |
Effect of antecedent hypertension and follow-up blood pressure on outcomes after high-risk myocardial infarction.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Captopril; Cardiovascular Diseases; Female; Follow-Up Studies; Heart Failure; Humans; Hypertension; Male; Middle Aged; Myocardial Infarction; Prognosis; Risk Factors; Stroke; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2008 |
Valsartan therapy in heart failure after myocardial infarction: the role of endothelial dependent vasorelaxation.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Thoracic; Blood Pressure; Dose-Response Relationship, Drug; Endothelium, Vascular; Heart Failure; In Vitro Techniques; Male; Myocardial Infarction; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Rats; Rats, Sprague-Dawley; Tetrazoles; Time Factors; Valine; Valsartan; Vasodilation; Ventricular Function, Left; Ventricular Remodeling | 2007 |
[The study of the effect of Cilazapril and valsartan on angiotensin 1 and angiotensin 2 receptors mRNA expression and myocardial interstitial collagen metabolism after myocardial infarction in rats].
Topics: Animals; Cilazapril; Collagen; Disease Models, Animal; Male; Myocardial Infarction; Myocardium; Random Allocation; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; RNA, Messenger; Tetrazoles; Valine; Valsartan | 2008 |
From black and white to shades of gray: race and renin-angiotensin system blockade.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Black or African American; Captopril; Heart Failure; Humans; Myocardial Infarction; Renin-Angiotensin System; Tetrazoles; United States; Valine; Valsartan; Ventricular Dysfunction, Left; White People | 2008 |
Racial analysis of patients with myocardial infarction complicated by heart failure and/or left ventricular dysfunction treated with valsartan, captopril, or both.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Black or African American; Captopril; Female; Heart Failure; Hospitalization; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Retrospective Studies; Risk Factors; Systole; Tetrazoles; United States; Valine; Valsartan; Ventricular Dysfunction, Left; White People | 2008 |
A common thrombomodulin amino acid dimorphism is associated with myocardial infarction.
Topics: Adult; Age of Onset; Alanine; Alleles; Codon; Disease Susceptibility; DNA Mutational Analysis; Female; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Point Mutation; Polymerase Chain Reaction; Polymorphism, Genetic; Polymorphism, Single-Stranded Conformational; Protein C; Thrombomodulin; Valine | 1997 |
Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 4th communication: improvement of heart failure of rats with myocardial infarction by valasartan.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Cardiomegaly; Enalapril; Male; Myocardial Infarction; Myocardial Ischemia; Myocardial Reperfusion Injury; Organ Size; Rats; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrazoles; Valine; Valsartan; Vascular Resistance; Ventricular Function, Left | 1997 |
Association of a common polymorphism in the factor XIII gene with myocardial infarction.
Topics: Case-Control Studies; Factor XIII; Female; Fibrinogen; Humans; Leucine; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Plasminogen Activator Inhibitor 1; Point Mutation; Polymorphism, Genetic; Risk Factors; Valine | 1998 |
C677T (thermolabile alanine/valine) polymorphism in methylenetetrahydrofolate reductase (MTHFR): its frequency and impact on plasma homocysteine concentration in different European populations. EARS group.
Topics: Adolescent; Adult; Alanine; Alleles; Europe; Gene Frequency; Genetics, Population; Genotype; Heterozygote; Homocysteine; Homozygote; Humans; Male; Methylenetetrahydrofolate Reductase (NADPH2); Myocardial Infarction; Oxidoreductases Acting on CH-NH Group Donors; Point Mutation; Polymorphism, Genetic; Valine | 1998 |
Polymorphisms of the tissue factor pathway inhibitor (TFPI) gene in patients with acute coronary syndromes and in healthy subjects : impact of the V264M substitution on plasma levels of TFPI.
Topics: Acute Disease; Adult; Aged; Amino Acid Sequence; Amino Acid Substitution; Angina, Unstable; Case-Control Studies; Coronary Disease; France; Gene Frequency; Genotype; Humans; Lipoproteins; Male; Methionine; Middle Aged; Molecular Sequence Data; Myocardial Infarction; Polymorphism, Genetic; Risk Factors; Syndrome; Valine | 1999 |
Valsartan and coronary haemodynamics in early post-myocardial infarction in rats.
Topics: Administration, Oral; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Body Weight; Cardiomegaly; Coronary Vessels; Dipyridamole; Dose-Response Relationship, Drug; Fibrosis; Hemodynamics; Male; Myocardial Infarction; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrazoles; Valine; Valsartan; Vasodilator Agents | 1999 |
Valsartan in acute myocardial infarction trial (VALIANT): rationale and design.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Captopril; Cause of Death; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Humans; Multicenter Studies as Topic; Myocardial Infarction; Odds Ratio; Patient Selection; Proportional Hazards Models; Randomized Controlled Trials as Topic; Research Design; Sample Size; Tetrazoles; Valine; Valsartan | 2000 |
Transcriptional and translational regulation of calpain in the rat heart after myocardial infarction--effects of AT(1) and AT(2) receptor antagonists and ACE inhibitor.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pressure; Calcium-Binding Proteins; Calpain; Disease Models, Animal; Gene Expression Regulation; Heart; Heart Rate; Imidazoles; Male; Myocardial Infarction; Protein Biosynthesis; Pyridines; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; RNA, Messenger; Tetrazoles; Transcription, Genetic; Valine; Valsartan | 2001 |
[Cardioprotective mechanism of ischemic preconditioning is impaired by postinfarct ventricular remodeling through angiotensin II type 1 receptor activation].
Topics: Angiotensin Receptor Antagonists; Animals; Ischemic Preconditioning, Myocardial; Myocardial Infarction; Rabbits; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Tetrazoles; Valine; Valsartan; Ventricular Remodeling | 2001 |
Combined angiotensin and endothelin receptor blockade attenuates adverse cardiac remodeling post-myocardial infarction in the rat: possible role of transforming growth factor beta(1).
Topics: Angiotensin Receptor Antagonists; Animals; Blotting, Northern; Bosentan; Collagen; Endothelin Receptor Antagonists; Female; Fibroblasts; Hemodynamics; Hypertrophy, Left Ventricular; Immunohistochemistry; Macrophages; Monocytes; Myocardial Infarction; Myocardium; Procollagen; Rats; Rats, Sprague-Dawley; RNA, Messenger; Sulfonamides; Tetrazoles; Time Factors; Transforming Growth Factor beta; Transforming Growth Factor beta1; Valine; Valsartan; Ventricular Dysfunction, Left | 2001 |
Effects of combination of angiotensin-converting enzyme inhibitor and angiotensin receptor antagonist on inflammatory cellular infiltration and myocardial interstitial fibrosis after acute myocardial infarction.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Collagen; Drug Combinations; Fibrosis; Fosinopril; Male; Myocardial Infarction; Myocardium; Random Allocation; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tetrazoles; Transforming Growth Factor beta; Transforming Growth Factor beta1; Valine; Valsartan; Ventricular Remodeling | 2001 |
Blockade of angiotensin II type 1 receptors suppressed free radical production and preserved coronary endothelial function in the rabbit heart after myocardial infarction.
Topics: Acetylcholine; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Endothelium, Vascular; Enzyme Inhibitors; Free Radicals; Hemodynamics; In Vitro Techniques; Lipid Peroxides; Male; Myocardial Infarction; Myocardium; Nitroprusside; omega-N-Methylarginine; Oxygen; Rabbits; Receptor, Angiotensin, Type 1; Tetrazoles; Tiopronin; Valine; Valsartan; Vasodilator Agents; Ventricular Remodeling | 2002 |
Decreases in repetitive extrasystole threshold in the conscious pig with myocardial infarct were reversed by tyrosine.
Topics: Animals; Arrhythmias, Cardiac; Blood Pressure; Cardiac Complexes, Premature; Catecholamines; Female; Heart Rate; Male; Myocardial Infarction; Random Allocation; Swine; Tyrosine; Valine | 1991 |
Elevation of serum transaminase activity for branched chain amino acids in dogs with experimental myocardial infarction.
Topics: Animals; Aspartate Aminotransferases; Dogs; Isoleucine; Leucine; Liver; Myocardial Infarction; Myocardium; Transaminases; Valine | 1968 |
[Levels of free amino acids in the blood and heart muscle in the human at various periods of myocardial infarct (clinical anatomical parallels)].
Topics: Alanine; Amino Acids; Arginine; Aspartic Acid; Chromatography; Erythrocytes; Glutamates; Glycine; Histidine; Histocytochemistry; Humans; Isoleucine; Leucine; Lysine; Methods; Middle Aged; Myocardial Infarction; Myocardium; Necrosis; Phenylalanine; Serine; Threonine; Time Factors; Tyrosine; Valine | 1968 |